The Turnaround Artists
These companies are led by elite CEOs with impressive track records of rescuing struggling businesses. Our analysts have carefully selected these stocks based on leadership that has the potential to engineer dramatic corporate revivals and create significant investor value.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Advanced Micro Devices, Inc.
AMD
Current price
$166.55
CEO Lisa Su orchestrated one of the most successful turnarounds in tech history, transforming the company from a struggling underdog into a leader in ...
CEO Lisa Su orchestrated one of the most successful turnarounds in tech history, transforming the company from a struggling underdog into a leader in high-performance computing.
Intel Corporation
INTC
Current price
$25.31
CEO Pat Gelsinger was brought back to lead a massive turnaround effort aimed at reclaiming the company's manufacturing and innovation leadership in th...
CEO Pat Gelsinger was brought back to lead a massive turnaround effort aimed at reclaiming the company's manufacturing and innovation leadership in the semiconductor industry.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
This portfolio focuses on companies that have appointed renowned executives to navigate through financial or operational challenges. We believe that exceptional leadership is often the key factor in transforming struggling companies into thriving businesses with strong stock performance.
What You Need to Know
This is a high-risk, high-reward investment theme with potential for volatility. The success hinges on the market's validation of new CEO strategies, typically seen through improved quarterly results. Early signs of turnaround can attract significant investor interest and potential price appreciation.
Why These Stocks
Each company in this collection has appointed a chief executive with a documented history of successfully reviving major corporations. We've focused on identifying proven “fixer” CEOs who have demonstrated their ability to create substantial value even under challenging circumstances.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+20.94%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 20.94% over the next year.
Stocks Rated Buy by Analysts
8 of 15 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 2.8% return last month.
Why You'll Want to Watch These Stocks
The Comeback Effect
When turnaround strategies start working, stock prices can recover dramatically as investor confidence returns. Early signs of success often lead to significant price momentum.
Elite Leadership Premium
These companies have attracted some of the most respected executives in business, creating the potential for transformative change that the market hasn't fully priced in yet.
Validator Moments Ahead
Each quarterly report provides an opportunity for these companies to prove their turnaround is working. Positive results can trigger rapid revaluation as institutional investors pile in.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.